Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Safety and Efficacy of Two Different Doses of Everolimus in Kidney Transplantation: A Systematic Review and Meta-Analysis Pubmed



Arabzozani M1 ; Mahdavimazdeh M2 ; Hasanpoor E3 ; Nejad DG4 ; Sokhanvar M5 ; Kakemam E6
Authors

Source: Iranian Journal of Kidney Diseases Published:2017


Abstract

Introduction. The aim of this systematic review and meta-analysis was to evaluate the efficacy-related events and adverse events of 2 different doses of everolimus in kidney transplant recipients. Materials and Methods. The Cochrane, PubMed, and Google Scholar databases were searched for randomized controlled trials published by the end of 2015 on the use of everolimus in kidney transplant recipients at doses of 1.5 mg/d and 3 mg/d. Two independent reviewers assessed the studies for quality and eligibility and extracted the data. The relative risk (RR) and 95% confidence interval (CI) for treated efficacy-related events and adverse events were collected to calculate pooled measures. Results. A total of 8 articles describing 7 randomized controlled trials (n = 2148 participants) were included in this study. The overall RR in adverse event outcomes was significantly in favor of the lower dose of everolimus (RR, 0.96; 0.95% CI, 0.93 to 0.99; P <.001). The overall risk of graft loss was lower with 1.5 mg/d of everolimus (RR, 0.76; 0.95% CI, 0.59 to 0.99; P =.04, I2 = 25.0%). There was no relationship between the rates of efficacy failure, biopsy-proven acute rejection, death, or loss to follow up outcomes in all the three follow-up times between the two doses of everolimus. Conclusions. The result of this systematic review and meta-analysis showed that the overall outcomes in adverse events and graft loss were better with everolimus, 1.5 mg/d, than with everolimus, 3 mg/d, when combined with other kidney transplantation medications. © 2017, Iranian Society of Nephrology. All rights reserved.
Other Related Docs
11. Herbal Medicines for Type 1 Diabetes Mellitus, Cochrane Database of Systematic Reviews (2015)
17. Antioxidant Supplements and Breast Cancer: A Systematic Review and Meta-Analysis, International Journal of Cancer Management (2018)